Clinical trials: Recurrent Neuroblastoma
Neuroblastoma
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
The purpose of this research study is to evaluate a new investigational drug to treat neuroblastoma. This study drug is called DFMO.
- Trial name
- NCT01059071
- Testing
- DFMO, Etoposide
- Where
- 7 sites in United States
- Volunteers
- 21 people
- Sponsor
- Giselle Sholler
Childhood Soft Tissue Sarcoma, Childhood Liver Cancer
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin in treating children who have…
- Conditions
- Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer, Brain Tumor
- Trial name
- NCT00019630
- Testing
- doxorubicin HCl liposome
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
This is a compassionate use protocol to allow patients with advanced neuroblastoma palliative access to 131I-metaiodobenzylguanidine (131I-MIBG).
- Trial name
- NCT01370330
- Testing
- Metaiodobenzylguanidine (MIBG)
- Where
- United States
- Sponsor
- Kieuhoa Vo
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
This phase I trial is studying how well ipilimumab works after allogeneic stem cell transplant in treating patients with persistent or progressive cancer.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00060372
- Testing
- ipilimumab, therapeutic allogeneic lymphocytes
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. This may be effective treatment for primary or metastatic brain tumors.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
- Trial name
- NCT00003461
- Testing
- surgical procedure, astatine At 211 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University
Neuroblastoma, Medulloblastoma
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
The purpose of this research study is to evaluate a new investigational drug (TPI 287) for neuroblastoma and medulloblastoma. An investigational drug is one that has not yet been approved by the Food and Drug Administration.
- Trial name
- NCT01483820
- Testing
- TPI 287
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- Giselle Sholler
Relapsed Neuroblastoma, Refractory Neuroblastoma
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma, Ganglioneuroblastoma
- Trial name
- DUAL-NK-NB (NCT07502287)
- Testing
- EB-DTNB-NK, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
This phase I trial is studying the side effects and best dose of tanespimycin in treating young patients with recurrent or refractory leukemia or selected solid tumors.
- Conditions
- Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor, Disseminated Neuroblastoma, Metastatic Childhood Soft Tissue Sarcoma
- Trial name
- NCT00093821
- Testing
- tanespimycin, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
RATIONALE: Methotrexate and glucocorticoid therapy, such as prednisone or methylprednisolone, may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell transplant.
- Trial name
- NCT00357084
- Testing
- methotrexate, methylprednisolone, prednisone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer, Head and Neck Cancer
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00937417
- Testing
- docetaxel, vandetanib, proteomic profiling
- Sponsor
- SWOG Cancer Research Network
Brain and Central Nervous System Tumors, Neuroblastoma
Vinorelbine in Treating Children With Recurrent or Refractory Cancers
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine in treating children with recurrent or…
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
- Trial name
- NCT00003234
- Testing
- vinorelbine tartrate
- Where
- 228 sites in United States, Australia and 5 more
- Volunteers
- 50 people
- Sponsor
- Children's Oncology Group
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent)…
- Conditions
- Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02304458
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 25 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Head and Neck Cancer
Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema
RATIONALE: Acupuncture and moxibustion may improve well-being and quality of life in patients with lymphedema caused by breast cancer or head, neck, and throat cancer.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lymphedema
- Trial name
- AMWELL-SL (NCT00828516)
- Testing
- Acupuncture and moxibustion
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- East and North Hertfordshire NHS Trust
High Risk Neuroblastoma, Recurrent Neuroblastoma
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
This phase II trial studies how well irinotecan hydrochloride, temozolomide, and dinutuximab work with or without eflornithine in treating patients with neuroblastoma that has come back (relapsed) or that isn't responding to…
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
- Trial name
- NCT03794349
- Testing
- Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride
- Where
- 145 sites in United States, Australia and 3 more
- Volunteers
- 94 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors, Neuroblastoma
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
RATIONALE: Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances, such as radioactive iodine, to them without harming normal cells.
- Trial name
- NCT00003484
- Testing
- carmustine, irinotecan hydrochloride, surgical procedure
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Darell D. Bigner, MD, PhD
Neuroblastoma
High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma
RATIONALE: Radioisotope therapy, such as iodine I 131 metaiodobenzylguanidine (MIBG), releases radiation that kills tumor cells.
- Trial name
- NCT00389766
- Testing
- iodine I 131 metaiodobenzylguanidine, topotecan hydrochloride, chemotherapy
- Sponsor
- Children's Cancer and Leukaemia Group
Recurrent Neuroblastoma, Neuroblastoma
Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma
Currently there is no known effective treatment for recurrent or resistant neuroblastoma. Fenretinide is an anticancer agent that may work differently than standard chemotherapy.
- Trial name
- SPOC2013-001 (NCT02163356)
- Testing
- Fenretinide/LXS Oral Powder, Ketoconazole, Vincristine
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- South Plains Oncology Consortium
Cancer
A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: A walking program may improve the ability to carry out daily activities after donor bone marrow transplant. PURPOSE: This randomized clinical trial is studying a structured walking program to see how well it works…
- Trial name
- NCT00445731
- Testing
- exercise intervention, management of therapy complications, observation
- Volunteers
- 115 people
- Sponsor
- University of Minnesota
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
There is a significant unmet medical need for effective therapies for pediatric relapsed/refractory solid tumors. EGFR is highly and stably expressed in multiple pediatric solid tumor subtypes, and adult Phase I data of Becotatug…
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
- Trial name
- MRG003 (NCT07584499)
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Chronic Myeloproliferative Disorders
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
RATIONALE: Antifungals such as ravuconazole may be effective in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection
- Trial name
- NCT00064311
- Testing
- ravuconazole
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)